Briacell Ebitda vs Reconciled Depreciation Analysis

BCTX Stock

USD 0.54 0.02 3.41%

Briacell Therapeutics financial indicator trend analysis is way more than just evaluating Briacell Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Briacell Therapeutics is a good investment. Please check the relationship between Briacell Therapeutics Ebitda and its Reconciled Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Ebitda vs Reconciled Depreciation

Ebitda vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Briacell Therapeutics Ebitda account and Reconciled Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Briacell Therapeutics' Ebitda and Reconciled Depreciation is -0.14. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Briacell Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Briacell Therapeutics' Ebitda and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Briacell Therapeutics Corp are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Ebitda i.e., Briacell Therapeutics' Ebitda and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.14

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ebitda

Reconciled Depreciation

Most indicators from Briacell Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Briacell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At this time, Briacell Therapeutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 77 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 4.2 M in 2024.

Briacell Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Net Receivables	Other Current Liab	Property Plant And Equipment Net	Inventory	Other Current Assets	Property Plant And Equipment Gross	Short Term Investments	Intangible Assets	Net Tangible Assets	Current Deferred Revenue	Net Invested Capital
Total Assets		-0.1	0.79	-0.98	-0.33	-0.05	0.98	-0.04	-0.1	0.98	0.45	0.54	0.72	0.52	0.98	0.02	-0.08	-0.05	0.09	0.35	-0.05	-0.45	0.42	0.84	-0.44	0.79
Total Current Liabilities	-0.1		-0.29	0.17	-0.75	0.92	-0.18	-0.08	0.93	-0.19	0.68	-0.07	-0.02	0.12	-0.14	0.9	0.19	-0.23	-0.93	0.22	-0.23	-0.51	0.41	0.06	-0.53	-0.24
Total Stockholder Equity	0.79	-0.29		-0.8	0.18	-0.22	0.8	0.09	-0.21	0.8	-0.07	-0.06	0.91	-0.1	0.77	-0.26	-0.14	0.11	0.22	-0.14	0.11	-0.16	0.17	0.89	-0.13	0.98
Net Debt	-0.98	0.17	-0.8		0.24	0.15	-1.0	0.19	0.19	-1.0	-0.37	-0.52	-0.69	-0.49	-1.0	0.09	0.03	0.18	-0.18	-0.3	0.18	0.41	-0.43	-0.84	0.42	-0.83
Retained Earnings	-0.33	-0.75	0.18	0.24		-0.76	-0.24	0.13	-0.7	-0.23	-0.98	-0.56	-0.03	-0.7	-0.3	-0.86	0.01	0.26	0.72	-0.67	0.26	0.62	-0.52	-0.23	0.65	0.13
Accounts Payable	-0.05	0.92	-0.22	0.15	-0.76		-0.16	0.05	0.99	-0.16	0.72	-0.07	0.05	0.1	-0.11	0.96	-0.19	-0.1	-0.99	0.18	-0.09	-0.36	0.21	0.13	-0.36	-0.19
Cash	0.98	-0.18	0.8	-1.0	-0.24	-0.16		-0.19	-0.19	1.0	0.36	0.52	0.69	0.49	1.0	-0.1	-0.03	-0.18	0.18	0.3	-0.18	-0.4	0.44	0.84	-0.43	0.83
Non Current Assets Total	-0.04	-0.08	0.09	0.19	0.13	0.05	-0.19		0.04	-0.19	-0.13	-0.17	0.2	-0.19	-0.2	0.01	-0.24	0.98	-0.03	-0.2	0.99	0.09	-0.33	-0.13	0.32	-0.12
Non Currrent Assets Other	-0.1	0.93	-0.21	0.19	-0.7	0.99	-0.19	0.04		-0.2	0.66	-0.15	0.03	0.02	-0.16	0.93	-0.18	-0.11	-0.99	0.09	-0.11	-0.31	0.24	0.12	-0.38	-0.18
Cash And Short Term Investments	0.98	-0.19	0.8	-1.0	-0.23	-0.16	1.0	-0.19	-0.2		0.35	0.52	0.69	0.49	1.0	-0.11	-0.04	-0.18	0.19	0.29	-0.18	-0.39	0.43	0.84	-0.42	0.83
Common Stock Shares Outstanding	0.45	0.68	-0.07	-0.37	-0.98	0.72	0.36	-0.13	0.66	0.35		0.62	0.09	0.74	0.42	0.81	-0.1	-0.24	-0.67	0.62	-0.24	-0.58	0.49	0.31	-0.63	-0.02
Non Current Liabilities Total	0.54	-0.07	-0.06	-0.52	-0.56	-0.07	0.52	-0.17	-0.15	0.52	0.62		-0.1	0.98	0.56	0.11	0.02	-0.16	0.13	0.71	-0.17	-0.34	0.34	0.09	-0.37	-0.03
Other Stockholder Equity	0.72	-0.02	0.91	-0.69	-0.03	0.05	0.69	0.2	0.03	0.69	0.09	-0.1		-0.09	0.68	0.03	-0.08	0.18	-0.05	0.08	0.18	-0.37	0.15	0.89	-0.16	0.87
Total Liab	0.52	0.12	-0.1	-0.49	-0.7	0.1	0.49	-0.19	0.02	0.49	0.74	0.98	-0.09		0.54	0.27	0.08	-0.22	-0.04	0.76	-0.22	-0.45	0.42	0.1	-0.48	-0.07
Total Current Assets	0.98	-0.14	0.77	-1.0	-0.3	-0.11	1.0	-0.2	-0.16	1.0	0.42	0.56	0.68	0.54		-0.04	-0.03	-0.19	0.15	0.37	-0.19	-0.43	0.45	0.84	-0.45	0.8
Net Receivables	0.02	0.9	-0.26	0.09	-0.86	0.96	-0.1	0.01	0.93	-0.11	0.81	0.11	0.03	0.27	-0.04		-0.16	-0.13	-0.93	0.41	-0.13	-0.41	0.29	0.15	-0.45	-0.23
Other Current Liab	-0.08	0.19	-0.14	0.03	0.01	-0.19	-0.03	-0.24	-0.18	-0.04	-0.1	0.02	-0.08	0.08	-0.03	-0.16		-0.23	0.14	0.13	-0.23	-0.49	0.28	-0.17	-0.27	-0.11
Property Plant And Equipment Net	-0.05	-0.23	0.11	0.18	0.26	-0.1	-0.18	0.98	-0.11	-0.18	-0.24	-0.16	0.18	-0.22	-0.19	-0.13	-0.23		0.13	-0.23	1.0	0.17	-0.41	-0.16	0.41	-0.1
Inventory	0.09	-0.93	0.22	-0.18	0.72	-0.99	0.18	-0.03	-0.99	0.19	-0.67	0.13	-0.05	-0.04	0.15	-0.93	0.14	0.13		-0.13	0.12	0.36	-0.22	-0.12	0.36	0.19
Other Current Assets	0.35	0.22	-0.14	-0.3	-0.67	0.18	0.3	-0.2	0.09	0.29	0.62	0.71	0.08	0.76	0.37	0.41	0.13	-0.23	-0.13		-0.23	-0.49	0.28	0.15	-0.35	-0.1
Property Plant And Equipment Gross	-0.05	-0.23	0.11	0.18	0.26	-0.09	-0.18	0.99	-0.11	-0.18	-0.24	-0.17	0.18	-0.22	-0.19	-0.13	-0.23	1.0	0.12	-0.23		0.17	-0.41	-0.16	0.41	-0.1
Short Term Investments	-0.45	-0.51	-0.16	0.41	0.62	-0.36	-0.4	0.09	-0.31	-0.39	-0.58	-0.34	-0.37	-0.45	-0.43	-0.41	-0.49	0.17	0.36	-0.49	0.17		-0.52	-0.36	0.6	-0.18
Intangible Assets	0.42	0.41	0.17	-0.43	-0.52	0.21	0.44	-0.33	0.24	0.43	0.49	0.34	0.15	0.42	0.45	0.29	0.28	-0.41	-0.22	0.28	-0.41	-0.52		0.37	-0.98	0.26
Net Tangible Assets	0.84	0.06	0.89	-0.84	-0.23	0.13	0.84	-0.13	0.12	0.84	0.31	0.09	0.89	0.1	0.84	0.15	-0.17	-0.16	-0.12	0.15	-0.16	-0.36	0.37		-0.38	0.92
Current Deferred Revenue	-0.44	-0.53	-0.13	0.42	0.65	-0.36	-0.43	0.32	-0.38	-0.42	-0.63	-0.37	-0.16	-0.48	-0.45	-0.45	-0.27	0.41	0.36	-0.35	0.41	0.6	-0.98	-0.38		-0.21
Net Invested Capital	0.79	-0.24	0.98	-0.83	0.13	-0.19	0.83	-0.12	-0.18	0.83	-0.02	-0.03	0.87	-0.07	0.8	-0.23	-0.11	-0.1	0.19	-0.1	-0.1	-0.18	0.26	0.92	-0.21

Click cells to compare fundamentals

Briacell Therapeutics Account Relationship Matchups

Briacell Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	478.3K	58.0M	42.6M	27.2M	5.9M	10.3M
Total Current Liabilities	3.6M	556.8K	941.1K	1.8M	7.5M	7.8M
Total Stockholder Equity	(3.3M)	57.3M	10.3M	(3.8M)	(2.4M)	(2.3M)
Net Debt	209.3K	(57.2M)	(41.0M)	(21.3M)	(862.1K)	(905.2K)
Retained Earnings	(16.6M)	(15.8M)	(60.3M)	(80.7M)	(85.4M)	(81.2M)
Accounts Payable	4.2K	214.1K	463.3K	1.1M	7.2M	7.5M
Cash	19.5K	57.3M	41.0M	21.3M	862.1K	819.0K
Non Current Assets Total	238.9K	245.6K	230.3K	215.1K	2.2M	1.2M
Cash And Short Term Investments	19.5K	57.3M	41.0M	21.3M	862.1K	819.0K
Common Stock Shares Outstanding	713.9K	4.5M	15.5M	15.6M	16.5M	17.3M
Liabilities And Stockholders Equity	478.3K	58.0M	42.6M	27.2M	5.9M	10.3M
Non Current Liabilities Total	142.8K	225.4K	31.3M	29.1M	1.1M	1.0M
Other Stockholder Equity	2.2M	39.0M	5.2M	7.4M	11.0M	8.1M
Total Liab	3.8M	782.2K	32.2M	30.9M	8.6M	4.8M
Total Current Assets	239.4K	57.8M	42.3M	26.9M	3.7M	3.5M
Net Receivables	20.6K	12.6K	24.1K	717.7K	1.4M	1.4M
Other Current Liab	3.4M	480.7K	741.8K	677.7K	290.4K	275.9K
Inventory	(305.0)	1.0	(24.1K)	(18.9K)	(1.4M)	(1.3M)
Other Current Assets	199.7K	516.9K	1.3M	5.0M	1.4M	721.5K
Accumulated Other Comprehensive Income	(81.0K)	(94.5K)	(127.0K)	(138.7K)	(124.8K)	(118.6K)
Intangible Assets	238.9K	245.6K	230.3K	215.1K	199.8K	182.9K
Net Tangible Assets	(1.2M)	(4.7M)	57.0M	10.1M	11.6M	11.5M
Net Invested Capital	(4.1M)	57.3M	10.3M	(3.8M)	(2.4M)	(2.3M)
Net Working Capital	(4.5M)	57.2M	41.4M	25.1M	(3.8M)	(3.6M)
Common Stock	11.2M	54.8M	65.6M	69.6M	72.2M	41.0M
Capital Stock	11.2M	54.8M	65.6M	69.6M	72.2M	45.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Briacell Ebitda vs Reconciled Depreciation Analysis

Ebitda vs Reconciled Depreciation

Ebitda vs Reconciled Depreciation Correlation Analysis

Correlation Coefficient

Ebitda

Reconciled Depreciation

Briacell Therapeutics fundamental ratios Correlations

Briacell Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Briacell Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Briacell Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Non Currrent Assets Other	+ 0.99	Accounts Payable
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Inventory	- 0.99	Non Currrent Assets Other
Inventory	- 0.99	Accounts Payable
Current Deferred Revenue	- 0.98	Intangible Assets